公开(公告)号：US20240238380A1

公开(公告)日：2024-07-18

申请号：US18562322

申请日：2022-05-20

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Do Hoon KIM ,  Mi Kyeong JU ,  Hyun Ho CHOI ,  Han Na HONG ,  Junhwan KIM

IPC: A61K38/26 ,  A61K38/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

CPC classification number: A61K38/26 ,  A61K38/1841 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome by administering in combination with a GLP-1 (glucagon-like peptide-1) receptor agonist, comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

公开(公告)号：US20190314452A1

公开(公告)日：2019-10-17

申请号：US16348249

申请日：2017-11-10

Applicant: YUHAN CORPORATION

Inventor： Han Na HONG ,  Jun Hwan KIM ,  Hyun Ho CHOI ,  Dohoon KIM ,  Taewang KIM ,  Se Woong OH ,  Moo Young SONG ,  Jong Gyun KIM

IPC: A61K38/18 ,  A61K38/26 ,  A61K38/17 ,  A61P1/16

Abstract: The present invention provides a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. Specifically, the present invention provides a fusion protein comprising a biologically active protein and an FGF21 mutant protein; and a pharmaceutical composition containing the fusion protein, which is effective for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. A pharmaceutical composition of the present invention has the effect of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used as a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.